Public universities can be negatively affected during a government shutdown — especially within its research department. Miguel Tovar/University of Houston

As the partial government shutdown loomed, academic institutions explored ways this might affect their research operations. Although we expect delays in processing proposals and award payouts, the impact on the institution may have been much less than expected. Consequently, most of the impact occurred at the individual principal investigator, or PI, level. That is where research that required federal resources came to a halt.

This is also the case for researchers at the Borders, Trade, and Immigration (BTI) Institute at the University of Houston. As a result of the shutdown, they were unable to start any new projects. Sadly, the government furloughed their program manager at the Department of Defense- Science and Technology Office of University Programs.

Education initiatives and multiple other research projects pending review were stuck along the "assembly line," as approvals did not happen during the month of January.

Consequently, BTI is a granted institution. Current projects were able to continue with slight delay due to the requirement to have meetings with the DHS representatives for their projects.

This scenario echoed across the research enterprise, as other researchers found themselves in similar situations.

Business as somewhat usual

Moreover, Nicholas Bond, climatologist and associate professor of atmospheric sciences at the University of Washington, felt the pinch of the shutdown and chronicled his experiences of how it impacted his research on climate and oceanography of the North Pacific.

Academic institutions across the country became burdened with the task of assuming unexpected financial responsibilities. In mid-January, the lapse in governmental funding forced The Ohio State University to temporarily cover the costs of unbilled expenditures to the tune of about $3 million. Harvard University continued to pay stipends for fellowships. They did this despite the fact that the shutdown included the federal funding agency.

Many faculty members, including our own, were able to continue working on their projects with the expectation of administrative delays. No new funding opportunities were issued, panel reviews were postponed and no new grants or no-cost extensions were awarded. For the most part, it was business as (somewhat) usual.

The big picture

It may be safe to say that the partial shutdown acted more as an inconvenience to the research enterprise than anything. Which is great news! Especially for the University of Houston, who has recently ignited the campus with the announcement of the 50-in-5 initiative. This ambitious program will increase the research and scholarly output by 50 percent over the next five years.

While this article focuses on the inconvenience of administrative delays, it's critical not to skim the surface. It may seem minute when compared to recipients of public assistance fearing not receiving benefits, but short-term implications are likely.

Keep in mind that most often, grants are not awarded by a single payment from the agency. Timelines are established between agencies and the institutions, and funds are released accordingly. Because of this, it's likely that research programs and educational initiatives across the academic research enterprise will not receive their funds on schedule.

What the future holds

Imagine, if you will, a conveyor belt. A system designed to allow items to move through a process with maximum efficiency. Because of the partial shutdown, research proposals that were in queue for review or funding experienced interruption along the conveyor belt.

Once disruptions to processes within federal agencies happen, it becomes inevitable that there will be delays further down the line.

Claudia Neuhauser, associate vice chancellor/vice president for Research and Technology Transfer for the UH System, warns of the "ripple effect" of the downstream delays and the potential impact on expenditures. We'll have to wait until the end of the year when annual reports are prepared for answers.

For now, it's a question of what the aftereffect will be.

------

This article originally appeared on the University of Houston's The Big Idea.

Nitiya Spearman is the internal communications coordinator for the UH Division of Research.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”